Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Moderna

This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate

RNA drug specialist Moderna also have their own OX40L candidate, mRNA-2416 in early stage trials.

Latest news

  • AZ makes gene therapy move with 4DMT alliance AZ makes gene therapy move with 4DMT alliance

    It also has a long-running collaboration with Moderna seeking messenger RNA drugs for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology, and is

  • Morning brief: New biotech launched, Merck and Moderna expand collaboration and more Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

    A rapid round up of pharma, biotech and healthcare news. Merck and Moderna expand cancer vaccines work. ... The two companies have now added to their collaboration shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer

  • BMS to explore new options for its immuno-oncology drug Opdivo BMS to explore new options for its immuno-oncology drug Opdivo

    Like BMS, Merck &Co has also moved to extend the reach of its immuno-oncology drug, teaming up with Moderna Therapeutics to develop personalised cancer vaccines that would work alongside Keytruda.

  • Merck & Co signs cancer vaccines research deal for Keytruda Merck & Co signs cancer vaccines research deal for Keytruda

    The deal with Moderna Therapeutics will see it use the Cambridge, Massachusetts-based company's novel messenger RNA (mRNA)-based vaccine technology. ... Moderna's mRNA vaccine technology uses the unique mutations present in a patient's tumour to provoke

  • mRNA - message received mRNA - message received

    Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious disease; metabolism. ... Valera LLC (Moderna Therapeutics). Infectious diseases. Merck &Co; Pasteur Institute. No clinical

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Deal Watch September 2016. Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up

  • Deal Watch June 2016 Deal Watch June 2016

    Apart from the $200m upfront cash payment to Moderna, there were no other financials disclosed. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).

  • Deal Watch October 2015 Deal Watch October 2015

    Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Quick links

Infographics

Multimedia